STANS, Switzerland,
June 2, 2021 /PRNewswire/ -- NLS
Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or
the "Company"), a Swiss clinical-stage pharmaceutical company
focused on the discovery and development of innovative therapies
for patients with rare and complex central nervous system
disorders, announces that Alex
Zwyer, Chief Executive Officer and Co-Founder, is scheduled
to present a corporate overview at the LD Micro Virtual
Invitational Conference being held on
June 8 – June
10, 2021.
Mr. Zwyer will deliver his corporate presentation on
June 10 at 11:30am ET, Track 2 and the presentation can be
viewed here. Investors attending the conference and interested in
scheduling a meeting with management should
contact assistant@ldmicro.com.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage
biopharmaceutical company led by an experienced management team
with a track record of developing and repurposing product
candidates to treat rare and complex central nervous system
disorders. The Company's lead product candidate,
Quilience® is a proprietary controlled-release
formulation of mazindol (mazindol CR), and is being developed for
the treatment of narcolepsy. Mazindol is a triple monoamine
reuptake inhibitor and partial orexin receptor 2 agonist, which was
used for many years to treat patients diagnosed with narcolepsy in
compassionate use programs. NLS completed a phase 2 study in the
U.S. evaluating mazindol CR in adult subjects with ADHD. The study
met all primary and secondary endpoints and was well-tolerated.
Quilience has received Orphan Drug Designations both in the U.S.
and in Europe for the treatment of narcolepsy.
Corporate Contact
Alex
Zwyer, CEO: +41 41 618 80 00
Investor Relations Contact
Cindy Rizzo: +1 908-229-7050
www.nlspharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nls-pharmaceutics-to-present-at-the-ld-micro-virtual-invitational-conference-on-june-10-2021-301302766.html
SOURCE NEUROLIFESCIENCES